LakePharma Announces Dedicated Vector Center to Support Gene and Cell TherapyAdded On: 2019-02-26
LakePharma Announces its GMP Biorepository Facility near Boston is Now Operational, Plans Additional HiringAdded On: 2019-01-15
LakePharma announces its cGMP microBiomanufacturing Center is now operationalAdded On: 2018-12-18
Added On: 2013-11-08
LakePharma was recently credited for its role with affinity measurements of the soluble production of biologically active single-chain antibodies against murine PD-L1 in Escherichia coli (E. coli). LakePharma calculated the binding kinetics (affinity measurements) of the surface plasmon resonance (SPR) using the ForteBio Octet QKe system. The study concluded that αPD-L1 scFv is an attractive alternative to full-length mAb for blocking PD-1/PD-L1 signaling for experimental purposes.
For more information on LakePharma’s role in this study, view the article:
Drees JJ, Augustin LB, Mertensotto MJ, Schottel JL, Leonard AS, Saltzman DA.
Protein Expr Purif. 2014 Feb;94:60-6.